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Background: There is very little literature regarding peripartum cardiomyopathy from the Asian countries.
We conducted this study to determine demographic details, clinical presentations, complications and recovery
of left ventricular (LV) systolic function in peripartum cardiomyopathy (PPCMP) patients of Pakistani origin.
Method: A ten year retrospective case series of PPCMP was conducted at the Aga Khan University Hospital.
Patients were also followed up for six months after presentation, with special regard to improvement in the LV
function.
Results: Total 45 patients were included, 25 (55.5%) primigravida and 8 (17.7%) gravida 2 and the remaining 12
(26.6%) were multigravida. Fourteen patients (31.1%) presented during pregnancy and 31 (68.8%) after delivery.
All patients presented with CHF and three (6.6%) were complicated with ventricular tachycardia (VT) at presentation.
LV systolic dysfunction was present in 39 (86.66%) patients and RV dysfunction in 15 (33.3%) patients. Two patients had
LV clot and thromboembolic stroke occurred in another 4 patients. All patients received standard treatment except
three patients who had asthma and could not be given beta blockers. Echocardiogram was repeated after 6 month
and in 32 (71.1%) patients LV functions recovered to normal. RV function improved in all except 2 (4.4%) patients.
All patients were discharged in stable condition.
Conclusion: Significant numbers of PPCMP patients, who had severe LV dysfunction at presentation recovered their
LV functions at six month follow up.
Keywords: Peripartum cardiomyopathy, Left ventricular systolic dysfunction, Right ventricular dysfunctionBackground
Peripartum cardiomyopathy (PPCMP) is a rare cause of
heart failure that affects women in the last month of
pregnancy or within 5 months of delivery [1]. PPCMP
was initially described in 1849 [2]. Other terms used for
this condition are toxic postpartum heart failure, Zaria
syndrome, Meadows’ syndrome and postpartum myocar-
diosis. The incidence of PPCMP varies extensively from
1:15,000 to 1:100 deliveries across geographic regions of
world [3]. The exact cause of the condition is not known,
with possible etiologies including genetic, inflammatory,
autoimmune and hormonal factors [4-6]. Management is
similar to that employed for other types of heart failure
with left ventricular systolic dysfunction with care how-
ever, to ensure the safety of the mother and the unborn or
breastfed baby. Cardiac transplantation is often the only* Correspondence: drabidlaghari@yahoo.com
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reproduction in any medium, provided the oracceptable treatment for patients in whom conventional
therapy is not successful. A number of factors are associ-
ated with increased risk, including age greater than
30 years [7], multiparity, African descent, pregnancy with
multiple fetuses [8], history of preeclampsia, eclampsia, or
postpartum hypertension, maternal cocaine abuse, long-
term (>4 weeks) oral tocolytic therapy with beta adre-
nergic agonists like terbutaline [9]. The echocardiogram
commonly reveals a global reduction in LV contractility
and enlargement without hypertrophy [10]. Our purpose
was to study the clinical profile of all patients that
presented to our center with this diagnosis.Methods
This was a descriptive study (case series) done at the
Aga Khan University Hospital (AKUH) by reviewing the
patients’ medical files from 1st June 2001 to 30th May
2011. The study was conducted after the ethical approvalLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient’s demographics at presentation
Number of cases (n) 45
Age range years 19 to 40
Mean age years 27.4 ± 6.05
Primigravida 25 (55.5%)
Multigravida 20 (44.4%)
Twin pregnancy 03 (6.6%)
Preeclampsia 04 (8.8%)
Eclapmsia 01 (2.2%)
Presentation during pregnancy 14 (31.1%)
Presentation after delivery 31 (68.8%)
Presentation (Average days after delivery) 02 - 60
Severe LV systolic dysfunction 39 (86.6%)
Moderate LV systolic dysfunction 06 (13.3%)
Severe MR 17 (37.7%)
Moderate MR 07 (15.5%)
Mild MR 14 (31.1%)
Table 2 Presentation, complication, LV and RV
improvement
CHF 45 (100%)
Arrhythmias (VT) 03 (6.6%)
Stroke (Ischemic) 04 (8.8%)
LV clot 02 (4.4%)
LV EF Improved (EF >50%) 32 (71.1%)
RV Function improved 43 (95.5%)
RV Dysfunction at 6 months 02 (4.4%)
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of the patients diagnosed with peripartum cardiomyopathy
were reviewed for age of the patient, gravid status, number
of fetuses, presenting features, clinical course and cardiac
complications during the index hospital stay. Echocardio-
graphic parameters including LV ejection fraction, RV
function and mitral regurgitation (MR) were noted at
presentation and after six months to see the course of
functional improvement in the systolic function.
Diagnostic criteria for PPCM
(1) Development of heart failure in the last month of
pregnancy or within 5 months of delivery; (2) absence of
another identifiable cause for the heart failure; (3) absence
of recognizable heart disease prior to the last month of
pregnancy; (4) left ventricular ejection fraction (LVEF) less
than 45% percent.
Recovery of LV function
Was defined as echocardiographic documentation of left
ventricular ejection fraction greater than or equal to 50%.
Standard treatment
All patients in the study received standard treatment in-
cluding loop diuretics, angiotensin converting enzyme
inhibitor (ACE inhibitor) / ARBs and beta-blockers, ex-
cept the few patients who had contraindication to spe-
cific medicine.
Results
Forty five patients of PPCMP were found through the
diagnosis coding system and their files were reviewed.
Patient age range was between 19 and 40 years (mean
age 27.4 ± 6.05). Majority of the (Table 1) patients 25
(55.5%) were primigravida and 8 (17.7%) patients were
gravida 2, remaining 12 (26.6%) patients were multigra-
vida. Three patients had twin fetuses. Fourteen patients
(31.1%) presented during pregnancy and the remaining
31 (68.8%) patients presented after delivery. Presentation
after delivery ranged from two days to two months. All
patients presented with symptoms and signs of heart
failure, four (8.8%) patients additionally had preeclampsia
and one had eclampsia. Three (6.6%) were complicated
with ventricular tachycardia at presentation. Majority of
the patients (86.66%) had severe left ventricular systolic
dysfunction (EF <30%) and 6 (13.3%) had moderate left
ventricular systolic dysfunction (EF <45% and >30%).
Similarly 17 (37.7%) patients had severe mitral regur-
gitation (MR), 7 (15.5%) had moderate MR and 14
(31.1%) patients had mild MR. RV dysfunction was
noted in 15 (33.3%) patients. Two patients had LV clot
and hospital course was complicated by thromboembolic
stroke in another four patients. All patients received
standard treatment except three patients who had asthmaand could not be administered beta blockers. Echocardio-
grams were repeated after six month and the majority
(71.1%) had recovered the LV functions (EF >50%).
Thirteen (28.8%) patients did not recover LV function
and had severe LV dysfunction (Table 2) (EF <30%) at
six months. In 13 patients who did not recover their LV
function; four had severe MR. In the group of patient in
whom LV function did not improve, majority (76.92%)
had age over 30 years, five (38.14) patients were gravida
2 and three (23.07%) patients were multigravida. The
patients who improved LV function at six months; there
also was a significant improvement in the MR. Right
ventricular function improved in the majority of patients,
only two patients (4.4%) had residual RV dysfunction at
six months. In our cohort all the patients were discharged
from hospital in a stable condition.
Discussion
The incidence of peripartum cardiomyopathy (PPCMP)
varies extensively across geographic regions of world
from 1:15,000 to 1:100 deliveries [3]. There is very little
literature from Asian countries. In a study from south
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case per 1374 live births [11]. The reported high incidence
of PPCMP in Nigeria (one case per 102 deliveries) [12]
may have an association to the local Hausa custom of
eating kanwa, a dry lake salt for 40 days after delivery [3].
The exact cause of PPCMP is still unknown and may be
multifactorial. Clustering of PPCMP in families has been
also published in case reports [13]. The hemodynamic
stress of gestational hypertension may contribute to the
development of heart failure [5]. However, in our study
only five (11.1%) patients had gestational hypertension.
Since the etiology of PPCMP is still unclear, a number of
factors have been associated with increased risk, including
age greater than 30 years, multiparity, African descent
[14], pregnancy with multiple fetuses [8], a history of pre-
eclampsia, eclampsia, postpartum hypertension, maternal
cocaine abuse, long-term (>4 weeks) oral tocolytic therapy
with beta adrenergic agonists such as terbutaline [9].
In our study 13 (28.8%) patients were more than
30 years age, 6.6% of patients had twin pregnancy and
four patients had preeclampsia. One patient was diag-
nosed with eclampsia. Three patients had asthma, who
received salbutamol inhalers (Beta agonist). Twenty
(44.4%) patients were multigravida. At our center patients
most commonly presented with symptoms of heart failure.
In our study four patients were complicated by cerebral
thromboembolic events during the clinical course. The
echocardiogram usually reveals a global reduction in
contractility and LV enlargement without hypertrophy
[10]. The majority of our patients had global left
ventricular dysfunction and 1/3rd had right ventricular
dysfunction as well. Other echocardiographic findings
include, regional heterogeneities of systolic wall thicken-
ing, left atrial enlargement, mitral and tricuspid regurgita-
tion [10]. The majority of our patients had associated MR
and most improved with improvement in the LV func-
tions. Atrial fibrillation occurs occasionally in patients
with PPCMP [12]. Sustained ventricular tachycardia has
rarely been reported with PPCMP. Three of our patients
(6.6%) had ventricular tachycardia (VT) at presentation.
Patients with PPCMP are at high risk for thrombus forma-
tion and thromboembolism due to the hypercoagulable
state of pregnancy and the stasis of blood secondary to se-
vere LV dysfunction [15]. Four of our patients had embolic
ischemic events and two patients had LV apical thrombus.
Limited data are available to guide the timing and mode of
delivery in PPCM. According to the 2010 European soci-
ety of cardiology working group statement, early delivery
is not required if the maternal and fetal conditions are
stable [16]. A number of studies have evaluated the out-
come of women with PPCMP [17]. The largest series of
123 cases of PPCMP showed a cardiac transplantation rate
of 4% and a mortality rate of approximately 10% at a mean
follow-up of about 2 years [17]. Recovery to an LVEFabove 50 percent occurred in 54% of patients, and the
degree of recovery was greatest in those with a baseline
LV ejection fraction >30% [17,18]. In our study 71.1% of
PPCMP patients recovered left ventricular ejection frac-
tion and the mitral regurgitation also improved in this
group. Baseline LVEF has limited sensitivity for prediction
of improvement in individual patients [19]. Most of our
patients (86.6%) had severe LV systolic dysfunction at
presentation.
Conclusion
In our study majority of the patients had severe LV dys-
function at time of presentation and a significant number
had recovery in their LV function at 6 months. Other than
more observed ventricular arrhythmias at presentation,
our study results are congruent with the international
literature.
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